bioMérieux S.A. (OTCMKTS:BMXMF – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $120.00 and last traded at $118.94, with a volume of 47 shares changing hands. The stock had previously closed at $117.01.
Wall Street Analysts Forecast Growth
Separately, UBS Group raised shares of bioMérieux to a “strong-buy” rating in a research report on Thursday, August 22nd.
Read Our Latest Analysis on bioMérieux
bioMérieux Price Performance
bioMérieux Company Profile
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Read More
- Five stocks we like better than bioMérieux
- What is the Australian Securities Exchange (ASX)
- Emerging Markets: What They Are and Why They Matter
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Recession or Not, These 3 Stocks Are Winners
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for bioMérieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMérieux and related companies with MarketBeat.com's FREE daily email newsletter.
